Type 1 Diabetes (T1D) Clinical Trials

Find Type 1 Diabetes (T1D) Clinical Trials Near You

Impact de l'Utilisation du système Mylife CamAPS FX associé au Capteur DEXCOM G6 Sur le contrôle glycémique et la qualité de Vie de Patients DT1, en Vie réelle, en France

Status: Recruiting
Location: See all (20) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY

This is a non-interventional, longitudinal, prospective, multicenter, post market-registration and national study conducted in France. The study is conducted among participants with type 1 diabetes (T1D) using the mylife CamAPS FX hybrid closed-loop insulin delivery system combined with the DEXCOM G6 Continuous Glucose Monitoring (CGM) sensor (the System). The main objective of the study is to evaluate, under real-life conditions, the impact of the System on glycemic control in participants with T1D after one year of use. Secondary objectives include assessing participant-reported outcomes, such as quality-of-life, treatment satisfaction, fear of hypoglycemia, and sleep quality, describing complications related to the system, the rate of hybrid closed-loop usage over one year, and analyzing system usage parameters (e.g., Boost/Ease-Off mode use, insulin-to-carbohydrate ratios, alarms). The study will involve approximately 125 participants (including 100 adults and 25 minors) across 20 centers in France. Endocrinologists / diabetes specialists will monitor participants over the 12-month period after they start using the system and collect data at the three data collection time points.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• Patients with type 1 diabetes who have been using a Dexcom or Abbott Libre glucose sensor (any model) for at least 14 days prior to the date of installation of the mylife YpsoPump, with at least 70% coverage, under the same sensor.

• Patient for whom the diabetes specialist decides to initiate the mylife CamAPS FX hybrid closed loop.

• Patient who received the information sheets and gave their consent to participate in the study and to the processing of their personal data.

• Adult patient who signed an informed consent form to participate in the study or minor patient whose parents signed an informed consent form for their child's participation in the study.

• Adult patient, minor patient old enough to complete the questionnaires or parent of a minor patient able to read and understand French.

• Adult patient / minor patient capable to complete the questionnaires or parent of a minor patient who agrees to complete the online self-questionnaires.

Locations
Other Locations
France
CHU Amiens
RECRUITING
Amiens
Hôtel Dieu-Pédiatrie
RECRUITING
Angers
CH Victor Dupouy
RECRUITING
Argenteuil
Hôpital Bois Guillaume
RECRUITING
Bois-guillaume
CHU Brest - Hôpital La Cavale Blanche
RECRUITING
Brest
Hôpital Femme Mère Enfant Lyon
RECRUITING
Bron
CHU Grenoble Alpes
RECRUITING
Grenoble
Groupe Hospitalier de la Rochelle Ré Aunis
RECRUITING
La Rochelle
Hospices Civils de Lyon DIAB-Ecare
RECRUITING
Lyon
Hôpital Européen
RECRUITING
Marseille
Groupe hospitalier Bichat Claude Bernard
RECRUITING
Paris
Hôpital Europeen Georges Pompidou
RECRUITING
Paris
Hôpital Universitaire Necker Enfants Malades
RECRUITING
Paris
CH Périgueux
RECRUITING
Périgueux
CHU Poitiers
NOT_YET_RECRUITING
Poitiers
Hôpital NOVO, Site Pontoise
RECRUITING
Pontoise
CHU Toulouse
NOT_YET_RECRUITING
Toulouse
CHRU Nancy-Hôpitaux de Brabois Adultes
RECRUITING
Vandœuvre-lès-nancy
CH Bretagne Atlantique
RECRUITING
Vannes
Hôpital Robert Schuman-UNEOS
RECRUITING
Vantoux
Contact Information
Primary
Emmanuel SONNET, MD
emmanuel.sonnet@chu-brest.fr
+33298347123
Time Frame
Start Date: 2025-12-11
Estimated Completion Date: 2027-12
Participants
Target number of participants: 125
Treatments
Participants with type 1 diabetes initiating the hybrid closed-loop system
Participants (adults and minors) with type 1 diabetes (T1D) initiating the mylife CamAPS FX system combined with the Dexcom G6 sensor, under real-life management conditions
Related Therapeutic Areas
Sponsors
Leads: mylife Diabetes Care AG
Collaborators: Qualees SAS, CamDiab Ltd

This content was sourced from clinicaltrials.gov